

Horizon Europe Funding Opportunities – 2021-2022

Health

ISERD is the interface between the Israeli government and the European Union, encouraging Israeli entities to participate in funding opportunities, and assisting in the process. ISERD holds events, information days, and [monthly Orientation Presentations](#) to give more information about funding opportunities

Horizon Europe -

[Horizon Europe](#) is a 95 billion euro funding programme for innovation and research, that covers all major scientific and technological disciplines, and encourages collaborative projects (consortium) for a joint goal.

- Consortium –
 - ✓ At least 3 partners from 3 different countries participating in the programme
 - ✓ Out of the 3, at least one partner must be from an EU country
 - ✓ A partner can be any legal entity – University, company, agency, organisation, etc...
- Funding Tools –

Action	Funding*	Main Characteristics
RIA – Research & Innovation Action	100% + 25%	Basic and applied research , technology development and integration, testing and validation - small-scale prototype in laboratory or simulated environment
IA – Innovation Action	70% + 25%	Prototyping , testing, demonstrating, piloting, large-scale product validation and market replication
CSA - Coordination & Support Action	100% + 25%	Networking , coordination or support services , policy dialogues and mutual learning exercises and studies

* Non profit – always 100%

ההשתתפות תלויה בחתימת מדינת ישראל על הסכם אסוציאציה לפני חתימה על הסכם הפרויקט;
הכתוב בעלון מבוסס על טיוטת התוכנית, ולפיכך נתון לשינויים – עד לאישור הסופי של תוכניות העבודה

Partner Search

Full Work
Programme

Previous Winning
Projects

Additional Funding
Opportunities

DISCLAIMER - The participation of Israeli entities, as associated country members in Horizon Europe projects is subject to the signing of the 'Association Agreement' to the programme between Israel and the EU.

For additional Information – Nir Shaked; nir.s@iserd.org.il;

Hagit Schwimmer; hagit.schwimmer@iserd.org.il;

Destination 1 - Staying healthy in a rapidly changing society

Call - Staying Healthy (one-stage 2021)

Code	Topic	Budget (M€)	Deadline: Two stages	No. of Projects	Type
HORIZON-HLTH-2021-STAYHLTH-01-02	Towards a molecular and neurobiological understanding of mental health and mental illness for the benefit of citizens and patients	10	21/09/2021	6	RIA
Advance the molecular and neurological understanding of how genetic, epigenetic, and environmental risk factors interact, and how and when psychosocial experiences become biologically embedded and drive mental illness.					
HORIZON-HLTH-2021-STAYHLTH-01-03	Healthy Citizens 2.0 - Supporting digital empowerment and health literacy of citizens	3	21/09/2021	1	CSA
Develop a strategy on digital health literacy, focusing on disease prevention, treatment, and self-care; involving non-health sectors impacting determinants of health, including environment, food, safety and occupational health.					
HORIZON-HLTH-STAYHLTH-2021-01-04	A roadmap for personalised prevention	3	21/09/2021	1	CSA
<ul style="list-style-type: none"> Identify and network key stakeholders, for the co-creation of personalised prevention strategy. Identify bottlenecks and analyse successful implementations of personalised prevention approaches, for transferability. Communicate the strategy to maximise its impacts and its uptake. 					

Call - Staying Healthy (Two stage - 2022)

Code	Topic	Budget (M€)	Deadline: Two stages	No. of Projects	Type
HORIZON-HLTH-STAYHLTH-2022-01-01-two-stage	Boosting mental health in Europe in times of change	7	01/02/2021 06/09/222	7	RIA
Develop and implement (pilot and/or scale-up) interventions, which promote wellbeing and prevent mental illness, to help cope with, and mitigate the stress of a changing society, including digital life, targeting relevant settings (e.g. workplaces, schools).					
HORIZON-HLTH-STAYHLTH-2022-01-04-two-stage	Trustworthy artificial intelligence (AI) tools to predict the risk of chronic non-communicable diseases and/or their progression	6	01/02/2021 06/09/222	10	RIA
<ul style="list-style-type: none"> Use existing data from multiple sources (i.e. cohorts, electronic health records and registries, etc.) and/or generate new data, to develop AI disease-risk prediction tools. Develop performance metrics to assess their accuracy, reliability, reproducibility and generalisability. Implement proof of concept and/or feasibility studies to validate the AI tools in a relevant real-world setting and assess their performance in comparison to the standard-of-care. 					
HORIZON-HLTH-STAYHLTH-2022-01-05-two-stage	Prevention of obesity throughout the life course	10	01/02/2021 06/09/222	6	2-stage RIA
<ul style="list-style-type: none"> Understand biological pathways conferring susceptibility to, and protecting against uncontrolled weight gain. Identify socio-economic & lifestyle factors influencing consumer behavior, associated to prevention. Identify pre-obesity biomarkers associated to lifestyle and environmental interventions tailored to target populations. Map existing research activities to prevent overweight/obesity, identify best practices. Conduct meta-review of scientific literature and identify the relationship between the risk for overweight/obesity and the biology of obesity, lifestyle habits, exposures, susceptibility to co-morbidities. Develop guidelines for healthy diet for different age and health groups. Understand the casual links between overweight/obesity and sedentary, quality & quantity of food/drinks, physical activity and personality traits. Design a creative and engaging programme to reach the optimal balance between diets and physical activity Analyse obesity stigma, stress and work-life balance, circadian rhythm disruption, mental health, screen-time, drugs, for the prevention of overweight/obesity. Address inequality aspects of overweight/obesity (e.g. vulnerable groups, gender and socio-economic factors). Set up pilots to assess the (cost)effectiveness of obesity management strategies Developing a system for monitoring population indicators 					

Call - Staying Healthy (Single stage - 2022)

Code	Topic	Budget (M€)	Deadline: Two stages	No. of Projects	Type
HORIZON-HLTH-STAYHLTH-2022-02-01-two-stage	Personalised blueprint of chronic inflammation in health-to-disease transition	7	21/04/2022	7	RIA
Develop personalised diagnosis and/or prevention strategies to chronic inflammation and assess the effects of different types of interventions and/or their combinations i.e. pharmacological, non-pharmacological, nutritional differences should be investigated, wherever relevant.					

Destination 2 - Living and working in a health-promoting environment

Call - Environment and health (2021)

Code	Topic	Budget (M€)	Deadline	No. of Projects	Type
HORIZON-HLTH-ENVHLTH-2021-02-01	Exposure to electromagnetic fields (EMF) and health	8	21/09/2021	4	RIA
Provide information on potential hazards and risks of EMF exposures through innovative monitoring techniques, experimental evidence and modelling.					
HORIZON-HLTH-ENVHLTH-2021-02-02	Indoor air quality and health	8	21/09/2021	5	RIA
Advance the understanding of the indoor air quality and related health and safety issues, related to chemical and biological indoor air pollution.					
HORIZON-HLTH-ENVHLTH-2021-02-03	Health impacts of climate change, costs and benefits of action and inaction	10	21/09/2021	6	RIA
Identify, monitor and quantify health impacts and risk factors correlated to climate change, using innovative surveillance tools to ensure timely response to emerging threats, to feed and strengthen early warning systems and to enable the design, monitoring and evaluation of interventions. This may include mathematical modelling with big data, AI, remote sensing, citizen science and biomarkers of exposure or virulence.					

Call - Environment and health (Single Stage 2022)

Code	Topic	Budget (M€)	Deadline	No. of Projects	Type
HORIZON-HLTH-ENVHLTH-2022-04-01	Methods for assessing health-related costs of environmental stressors	4	21/04/2022	5	RIA
Improve the calculation of the socio-economic costs (or benefits) of health impacts during the life-course associated to environmental stressors, and advance methodological approaches and foster their acceptance as common good practice.					

Destination 3 – Tackling diseases & reducing disease burden

Call - Tackling diseases (2021)

Code	Topic	Budget (M€)	Deadline	No. of Projects	Type
HORIZON-HLTH-2021-DISEASE-04-01	Improved supportive, palliative, survivorship and end-of-life care of cancer patients	6	21/09/2021	8	RIA
Strengthen the evidence base for patient-centred, effective interventions improving quality of life and outcomes of cancer patients and cancer survivors of all ages in the domains of palliative, supportive, survivorship, and end-of-life care. SSH .					
HORIZON-HLTH-DISEASE-2021-04-02	Building a European innovation platform for the repurposing of medicinal products	25	21/09/2021	2	RIA
<ul style="list-style-type: none"> Set up a platform supporting an innovative repurposing model, integrating scientific, methodological, financial, legal, regulatory, and intellectual property aspects of the repurposing approach. Provide selection mechanisms for prioritising repurposing projects, based on unmet needs. pool and share existing high-quality data assets, by using pharmacogenomics, in silico, and AI approaches, and deliver new computational tools. Resolve fragmentation and lack of ownership of the repurposing approach, networking existing initiatives. 					
HORIZON-HLTH-2021-DISEASE-04-03	Innovative approaches to enhance poverty-related diseases research in sub-Saharan Africa	8	21/09/2021	5	RIA
<ul style="list-style-type: none"> Implement one or more medium-scale clinical trials and/or clinical research studies that can deliver proof-of-concept or validation of smart, highly innovative technologies or concepts to prevent, treat or diagnose Poverty Related Infectious Disease (PRDs) in sub-Saharan Africa, drawing lessons from the COVID-19 experience. Address PRD or group of PRDs affecting sub-Saharan Africa (within the scope of EDCTP2 / EDCTP3). Combine medical & pharmaceutical technologies with digital, mobile, big data and other ICTs. Include pharmaceuticals and SMEs in the consortium and collaborate with EDCTP projects in the area. 					
HORIZON-HLTH-2021-DISEASE-04-04	Clinical validation of artificial intelligence (AI) solutions for treatment and care	6	21/09/2021	10	RIA

Implement clinical studies to validate clinically AI-based solutions at late stages of (pre)clinical development, comparing their benefit versus standard-of-care treatments in non-communicable diseases.

Address usability, performance and safety of the developed AI solutions, their clinical evaluation and (cost-)effectiveness in view of their inclusion into current clinical guidelines for personalised treatments following current EU regulatory framework.

HORIZON-HLTH-DISEASE-2021-04-05	A roadmap towards the creation of the European partnership on One Health antimicrobial resistance (OH AMR)	1	21/09/2021	1	CSA
---------------------------------	--	---	------------	---	-----

Develop a Strategic Research and Innovation Agenda (SRIA) for a comprehensive approach to inform the future candidate Partnership on One Health antimicrobial resistance.

Integration of key actors for AMR encompassing the field of human, veterinary and environmental disciplines and the broad spectrum of pathogens, including fungi and viruses.

Robust communication and effective information exchange between diverse scientific disciplines and among multiple sectors of the society that are implicated – patients, clinicians, veterinarians, pharmacists, food producers and representatives of the pharmaceutical industry, and policy makers.

HORIZON-HLTH-2021-DISEASE-04-06	Building a European partnership for pandemic preparedness	2	21/09/2021	1	CSA
---------------------------------	---	---	------------	---	-----

Improve the EU's preparedness to predict and respond to emerging infectious health threats by better coordinating funding for R&I at EU, national (and regional) level towards jointly agreed objectives and an agreed strategic R&I agenda.

HORIZON-HLTH-2021-DISEASE-04-07	Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g. SARS-CoV-2)	7	21/09/2021	9	RIA
---------------------------------	--	---	------------	---	-----

Characterize the host response and host-pathogen interaction to a virus (or viruses) at the level of genetic patterns, physiological mechanisms and molecular pathways involving different organs and systems to identify factors that predispose to different clinical symptoms, different progression of the viral disease and different clinical outcomes.

Destination 3 – Tackling diseases & reducing disease burden

Call - Tackling diseases (Two Stage - 2022)

Code	Topic	Budget (M€)	Deadline	No. of Projects	Type
HORIZON-HLTH-2022-DISEASE-06-02-two-stage	Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs	6	01/02/2022 06/09/2022	10	RIA 2-stage
Study and develop Immunotherapy agents, such as antibody-based, RNA-based and cell-based therapies, aiming at the pre-clinical to first-in human, in order to improve and diversify the health standards of care of several communicable or non-communicable diseases that cannot be effectively tackled with the current available treatments, excluding cancer.					
HORIZON-HLTH-2022-DISEASE-06-03-two-stage	Vaccines 2.0 - developing the next generation of vaccines	5	01/02/2022 06/09/2022	8	RIA 2-stage
Diversify and accelerate the global vaccine R&D pipeline, covering pathogens which lack sufficiently efficacious vaccines, but where earlier efforts have already produced vaccine candidates.					
<ul style="list-style-type: none"> • Innovation and integration of expertise and capabilities, including alignment of preclinical and clinical models, biomarker studies and new vaccine approaches from discovery to late stage development, from bench-based research to clinical development of promising preventive candidates. • Integrative analysis of data. Application of iterative processes to allow exploitation and integration of novel findings between clinical, preclinical and discovery. • Deciphering mechanisms of protection of candidates, new approaches to antigen discovery and immunogen engineering, reverse vaccinology, evaluation of vaccines in novel platforms and technologies, novel adjuvants, innovative vaccine manufacturing approaches, relevant animal models, evaluation of alternative vaccine delivery routes. • Effective, evidence-based decision-making for progression of vaccine candidates in the pipeline based on transparent and objective portfolio management. Regulatory requirements should be considered. 					

HORIZON-HLTH-DISEASE-2022-06-two-stage-04	Development of new effective therapies for rare diseases	8	01/02/2022 06/09/2022	8	RIA 2-stage
<p>Develop therapies for rare diseases with no approved therapeutic option, focusing on <u>group(s)</u> of rare diseases (NOT a single disease) with commonalities, such as shared biological features. Therapies may include a broad family of therapeutic interventions, such as small molecule(s), advanced therapy medicinal products, repurposing existing therapies, including non-pharmacological interventions and/or their combinations.</p> <p>Proposals may cover different stages of development (i.e. translational, preclinical, clinical research, validation in the clinical and/or real-world setting etc.).</p> <p>Rare infectious diseases and rare cancers will not be considered in this call.</p>					

Destination 3 – Tackling diseases & reducing disease burden

Call - Tackling diseases (Single Stage - 2022)

Code	Topic	Budget (M€)	Deadline	No. of Projects	Type
HORIZON-HLTH-2022-DISEASE-07-01	Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)	2	21/04/2022	1	CSA
HORIZON-HLTH-2022-DISEASE-07-02	Pandemic preparedness	3	21/04/2022	3	RIA
<p>Address priority research and innovation gaps that would support the establishment and work of a potential future Health Emergency Preparedness and Response Authority (HERA). Focus on 'pathogen X' from threat assessment, horizon scanning for the identification of potential medical countermeasures and innovative technologies and develop standardised research protocols.</p>					

HORIZON-HLTH-2022-DISEASE-07-03	Non-communicable diseases risk reduction in adolescence and youth (Global Alliance for Chronic Diseases - GACD)	3	21/04/2022	8	RIA
<p>Implement scientific research around evidence-based interventions that promote healthy behaviours and lifestyle and that have a potential to profoundly reduce the risk of chronic diseases and multimorbidity in young people (10-24), in order to understand the uptake, accessibility, acceptability, adaption, sustainability and costs of known interventions for use in young adults and adolescents.</p> <p>Focus on interventions that and make a case for why the selected life stage is a critical period for the reduction of NCD risk in the communities where the research will be undertaken.</p> <p>All partners are expected to have a meaningful engagement throughout all phases of the project, not only as participants in the research undertaken.</p>					

Destination 4 – Ensuring access to innovative, sustainable & high-quality Healthcare

Call - Ensuring access to innovative, sustainable & high-quality Healthcare (2021)

Code	Topic	Budget (M€)	Deadline	No. of Projects	Type
HORIZON-HLTH-CARE-2021-05-01	Enhancing quality of care and patient safety	5	21/09/2021	5	RIA
<p>Develop and implement coherent quality improvement and patient safety strategies in Europe, including harmonisation and standardisation of health care processes - Guidelines and Standard Operating Procedures - along the continuum of care, in order to contribute to an improved quality and safety of health services, and to minimise the risk of errors, and at the same time ensure the quality and comparability of health data.</p>					
HORIZON-HLTH-2021-CARE-05-02	Data-driven decision-support tools for better health care delivery and policy-making with a focus on cancer	10	21/09/2021	4	RIA
<p>Optimising and/or transforming health and care delivery decision-making processes, supporting policy-making, and/or empowering citizens and cancer patients. Proposals must focus on one or more of the cycles of cancer disease, starting from prevention and early diagnosis to treatment and quality of life of patients and survivors.</p> <p>Applicants should propose activities underpinned by healthcare data in one or more of the following areas:</p>					

- Develop of data-driven, interactive policy and visualisation tools (i.e. through creation of digital twins /virtual models) bringing novel insights on populations, systems and services, to help policy-makers make data-driven decisions.
- Develop data-driven solutions (i.e scenario-building tools, models) helping healthcare organisations take evidence-informed decisions on cancer care delivery processes such as logistics planning and management, capacity, utilisation of health services and allocation of resources and infrastructures (i.e. human resources, health goods, among others), and availability of and access to health and care technologies (i.e. pharmaceuticals, vaccines, medical devices, etc.) and interventions;
- Develop data-driven solutions empowering citizens and cancer patients interaction with the health and care systems, including feedback mechanisms, guidance on health and care pathways and on managing healthcare data, supporting patients in making healthcare decisions and treatment adherence;
- Develop digital toolkits and indicators to improve the reporting and assessment of outputs from end-user involvements including of patient-reported outcomes measures (PROMs) and patient-reported experience measures (PREMs), and help gauge the actual impact in health and care (including interaction between patients and health care providers).

HORIZON-HLTH-CARE-2021-05-04	Health care innovation procurement network	5	21/09/2021	1	CSA
------------------------------	--	---	------------	---	-----

Proposals should include all of the following aspects:

- Hold an open market consultation with the industry across Europe on the current state of the art for the shared unmet needs for innovative solutions identified by the procurers, including on technical and service readiness;
- Develop cooperation models for implementing Pre-Commercial Procurement and Public Procurement of Innovative solutions, which overcome potential differences among the legal public procurement frameworks of the participating procurers in health and social care;
- Conduct a market analysis and propose solutions to overcome potential barriers (standardisation, certification, regulatory requirements, intellectual property rights, contracting models, payment/reimbursement models);
- Consult with relevant stakeholders, end-users (consumer organisations, reimbursement bodies) to prepare for a future market uptake of the solutions;

Take measures ensuring the sustainability of outcomes beyond the lifespan of the proposed project and their integration into the procurement strategies of participating organisations, considering acceptance with users and professionals as well as health economics considerations.

HORIZON-HLTH-2022-CARE-08-04	Better financing models for health systems	5	21/04/2022	6	RIA
------------------------------	--	---	------------	---	-----

HORIZON-HLTH-2022-IND-13-03	New pricing and payment models for cost-effective and affordable health innovations	5	21/04/2022	3	RIA
-----------------------------	---	---	------------	---	-----

Destination 5 – Unlocking the full potential of new tools, technologies and digital solutions for a healthy society

Call – Tools and technologies for a healthy society (2021)

Code	Topic	Budget (M€)	Deadline	No. of Projects	Type
HORIZON-HLTH-2021-TOOL-06-01	Smart medical devices and their surgical implantation for use in resource-constrained settings	6	21/09/2021	4	IA
<ul style="list-style-type: none"> Design and develop surgically-implanted active "smart" medical devices (i.e. micro-electronic sensor-/actuator systems), usage is open for applicants choice (e.g. orthopaedic, neural, cardiovascular, metabolic, etc.), starting at a TRL 4 or above, addressing challenges such as miniaturization, sensor robustness, wireless power supply, etc. Develop minimally-invasive affordable surgical intervention for implanting the device, suitable for resource-limited clinical settings, such as lack of medical staff, scarcity of medical equipment or medicines supply, etc. R&I activities should comprise medical device design, regulatory work, clinical stages and developmental iterations, reaching a TRL of at least 7, and involve key medical specialists (e.g. surgeons) and/or other healthcare professionals, developers, patients and relevant regulatory bodies as appropriate. 					
HORIZON-HLTH-2021-TOOL-06-02	Next generation advanced therapies to treat highly prevalent and high burden diseases with unmet medical needs	6	21/09/2021	10	RIA
<p>Develop preclinical research platforms for disorders with high prevalence and burden that are clear and justified, in one or several of the following unmet needs, considering the Oviedo Convention, eligible actions and ethical principles as defined by the regulation:</p> <ul style="list-style-type: none"> Develop a method for the production and differentiation of pluripotent stem cells (defined as cells that can give rise to cells from all three embryonic germ layers), to include defining appropriate potency assays. Develop and validate biological assays and methods that can demonstrate efficacy, delivery, specificity, and safety of genome editing products in targeted cells and tissues (e.g. base editing, prime editing, talens, zinc-finger nucleases, CRISPR). Develop and validate novel RNA-based therapeutics targeting non-communicable diseases. Complementary activities to assess mode of action, delivery, safety in vivo validation and/or upscaling procedures could be considered. Study, analyse and tackle different immune responses, considering factors like sex and age, generated by any of the above-mentioned advanced therapies in vivo, facilitating regulatory approval for next phase of R&D. 					

HORIZON-HLTH-2021-TOOL-06-03	Innovative tools for use and re-use of health data (in particular of electronic health records and/or patient registries)	8	21/09/2021	4	RIA
------------------------------	---	---	------------	---	-----

Proposals should address all the following aspects:

- Develop robust novel solutions compliant with legal requirements, that will improve the quality, interoperability, machine-readability and re-use of health data and metadata in compliance with FAIR data management principles, making these data more accessible to clinicians and researchers and citizens. Focus on data in electronic health records (EHRs) and/or patient registries, considering the Commission Recommendation on a European Electronic Health Record exchange format.
- Develop innovative natural language processing tools, including computational semantics, ontologies, text mining, associated machine learning and deep learning, to improve accessibility, interoperability, translation, transcription, and analysis of health data (e.g. to predict risks). Tools should extract health information from unstructured data in different clinical and medical sources and bring that data into EHRs/ patient registries in a structured form. The innovative solutions should also address missing data in EHR and/or patient registries and their related metadata, to reduce bias and improve the quality of conclusions.
- Develop and pilot AI-powered virtual assistants that will utilise the tools and solutions to demonstrate improved usability of health data for end-users.

Destination 5 – Unlocking the full potential of new tools, technologies and digital solutions for a healthy society

Call – Tools and technologies for a healthy society (Single Stage - 2022)

Code	Topic	Budget (M€)	Deadline	No. of Projects	Type
HORIZON-HLTH-TOOL-2022-11-01	Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers	10	21/04/2022	6	RIA

- Clinically validate qualified biomarkers (not limited to molecular biomarkers) to ensure an effective and efficient use of existing pharmaceuticals that are already on the market, in the treatment of major diseases and conditions (excluding Cancer and rare diseases).
- Preliminary studies or publications have demonstrated that the pharmaceuticals considered are efficient in less than 50% of the population treated.

- The biomarkers should allow providing personalised medicinal product, dosage and timing, considering differences in sex, age, ethnicity and gender identity.

HORIZON-HLTH-TOOL-2022-11-02	New methods for the effective use of real-world data and/or synthetic data in regulatory decision-making and/or in health technology assessment	7	21/04/2022	5	RIA
------------------------------	---	---	------------	---	-----

Address the data needs of health regulatory bodies and Health Technology Assessment bodies across Europe, driving up the quality of evidence and decisions on the development and use of medicines and digital health innovations.

Destination 5 – Unlocking the full potential of new tools, technologies and digital solutions for a healthy society

Call – Tools and technologies for a healthy society (2022)

Code	Topic	Budget (M€)	Deadline	No. of Projects	Type
HORIZON-HLTH-2022-TOOL-12-01-two-stage	Computational models for new patient stratification strategies	6	21/04/2022	10	2-stage RIA

Proposals should address several of the following areas:

- Establish interdisciplinary research by bridging disciplines and technologies (disease biology, clinical research, data science, -omics tools, computational and mathematical modelling of diseases, advanced statistical and/or AI/machine learning methods, Virtual Physiological Human and/or digital twin technologies).
- Develop new computational models for the integration of complex health data from multiples sources.
- Develop and optimise robust, transparent and accurate computational models to guide patient stratification strategies for improving clinical outcomes.
- Demonstrate, test and clinically validate models, to stratify patients for an improved standard-of-care.

Develop new patient stratification strategies guided by computational models and the validation of the new concepts of stratification in pre-clinical and/or clinical studies.

Destination 6 – Maintaining an innovative, sustainable and globally competitive health industry

Call – A competitive health-related industry (2021)

Code	Topic	Budget (M€)	Deadline	No. of Projects	Type
HORIZON-HLTH-2021-IND-07-01	Green pharmaceuticals	8	21/09/2021	5	RIA
HORIZON-HLTH-2021-IND-07-02	Development, procurement and responsible management of new antimicrobials	2	21/09/2021	1	CSA

- Research and innovation to support the development of “greener” pharmaceuticals that degrade more readily to harmless substances in waste water treatment plants and the environment;
- Research on the eco-toxicity and environmental fate of pharmaceuticals, in particular those that are not yet subject to environmental risk assessment.
- Propose innovative manufacturing technology that are greener, low in energy consumption and emissions, using less solvent or recycling solvents;
- Propose methods for eliminating carcinogenic impurities in pharmaceuticals (e.g. nitrosamines) process and medicinal products, in particular as complementary technologies to the manufacturing methods relying on recycled solvents;
- Explore innovative uses of digital transformation or robotic for competitive and scalable methods of production;

Establish an innovation partnership as a pull incentive for new antimicrobials where there is an unmet medical need and a market failure. takes place in three phases:

1. Competitive phase - the most suitable partner(s) are selected based on their capacity. The contracts establishing the innovation partnership are awarded using the criteria of the best price-quality ratio proposed.
2. R&D phase – the partner(s) will develop new solution in collaboration with the contracting authority.
3. Commercial phase - the partner(s) provide the results.

Proposals of this topic should follow the specific requirements for the Innovation partnership.

Procurers of the antimicrobials to be developed together with the Commission are forming the contracting authority that sets out the requirements and conditions for the product(s) to be developed through this partnership. This will be guided by public health needs and should be based on priority pathogens such as those identified by WHO. The call will invite developers to partner with contracting authority to develop antimicrobials that meet the requirements.

HORIZON-HLTH-2021-IND-07-03	Promoting a trusted mHealth label in Europe: uptake of technical specifications for quality and reliability of health and wellness apps	2	21/09/2021	1	CSA
-----------------------------	---	---	------------	---	-----

The proposals are expected to address all of the followings:

- Set up a structured dialogue on the uptake of the Technical Specifications, between app developers, health and care system representatives, app stores, medical societies, patient organisations, users (incl. health and care professionals) and certification bodies, building a digital ecosystem around a trustable mHealth label.
- Co-create, develop, and implement an action plan to promote the mHealth label.
- Implement actions on the integration and use of Health and Wellness Apps, using the new label, in specific health and care settings, covering the entire European Union.
- Ensure Apps are bias-free and address the needs of different social groups (gender, age, ethnicity, etc.)
- Set-up an inclusive dissemination strategy to promote the use of the mHealth app quality label (cfr. EU energy labels and EU Nutri-Score nutrition label) considering the different levels of digital health literacy.
- Interests of different age groups, sex and gender, as well as other categories like persons with disability, ethnicity and the LGBTI+ community should be considered, where relevant

Destination 6 – Maintaining an innovative, sustainable and globally competitive health industry

Call – A competitive health-related industry (2022)

Code	Topic	Budget (M€)	Deadline	No. of Projects	Type
HORIZON-HLTH-IND-2022-13-01	Enhancing cybersecurity of connected medical devices	6	21/04/2022	3	RIA
<p>Proposals need to address some or all the followings:</p> <ul style="list-style-type: none"> Systematic review of current standards/guidelines/best practices applied to cybersecurity of connected medical devices, to identify and specify gaps and requirements based on evidence. Propose risk benefit analysis schemes for cybersecurity of connected medical devices, considering several novel technological developments (e.g. 5G networks, big data, artificial intelligence, cloud computing, augmented reality, blockchain) and interconnection architectures. Explore, develop, and validate novel methodologies and toolboxes for ensuring cybersecurity by design. Identify case studies, evaluate the applicability of existing guidance MDCG 2019-16 - Guidance on Cybersecurity for medical devices and make recommendations to (better) address specificities of the connected medical device, including software, of different risk classes. 					
HORIZON-HLTH-IND-2022-13-02	Scaling up multi-party computation, data anonymisation techniques, and synthetic data generation	7	21/04/2022	4	RIA
<p>Address the following:</p> <ul style="list-style-type: none"> Consolidate and scale multi-party computation and data anonymisation techniques and synthetic data generation Develop unbiased AI based and distributed tools and digital solutions, while maintaining data privacy. Advance the state-of-the-art of de-identification, for anonymised datasets that trace back to individuals. Develop anonymisation techniques demonstrating effective data quality without compromising privacy. Develop techniques of creating synthetic data, also dynamically on demand for specific use cases. Widen the basis for GDPR-compliant research and innovation on health data. Ensure uptake and scalability of the methodologies and tools developed, promote high standards of transparency. 					
HORIZON-HLTH-IND-2022-13-04:	Setting up a European Smart Health Innovation Hub	2	21/04/2022	1	CSA
<ul style="list-style-type: none"> Promote networking, synergies and exchange of knowledge and best practices between different actors – working on digital health solutions, including training to end-users and deployment strategies. Promote scalability of digital innovation solutions by organising marketplaces and pitching events to public health organisations and private entities and by involving industry and Member States representatives. 					

- Integrating existing repositories into a sustainable European repository, serving as a reference of ready to market solutions (supply side) and public and private organisations adopting them (demand side), and best practices.
- Match the needs of all citizens and patients, regardless of their age, gender, social or economic background.

HORIZON-HLTH-IND-2022-13-05	Setting up a European Electronic Health Record Exchange Format (EEHRxF) Ecosystem	2	21/04/2022	2	CSA
-----------------------------	---	---	------------	---	-----

Develop interoperable cross-border digital health solutions for individuals, researchers, health services and the workforce across the EU will be significantly improved and supported by a sophisticated ICT toolbox, representative use case applications, a Pan-European ecosystem of early adopters, and a framework for sustainability and exploitation.